Immediate Reports All 2019 2018 2017 2016 זימון אסיפה ל-14.3.19-עדכון מדיניות תגמול לדירק’ ונ.משרה,תנאי כהונת מנכל ויור כולל הקצאת אופ+RSU ועוד,כתב הצבעה ועוד החלטת ביהמ”ש לאישור שינוי תנאי אופציה סדרה 2,הגשת התנגדויות תוך 10 ימים הסדר/ פשרה/ הקפאת הליכים, פניה לבית משפט תוצ’ אסיפת כ.אופ 2 מיום 30.1.19-אישור הסדר להארכת תקופת מימוש אופ 4 עד 30.4.19 החלטות דירק’-מד. תגמול,תנאי העסקת מנכל ויו”ר,שירותי יעוץ ומינוי דירק’, כפוף לאישור האסיפה קרדיאקסנס(כ7.45%)-תחילת ניסוי קליני ראשוני לבחינת זיהוי פרפור עליות בתנאים אמבולטוריים Merchavia Holdings completes successful offering in TASE Merchavia signs MoU for first investment in the medical cannabis sector Merchavia’s portfolio company ‘Juventas’ announces strategic commercialization agreement הוחלט על הרחבת פעילות וכניסה לתחום מו”פ של קנאביס רפואי תשקיע ב-G4P-חב’ בתחום הבריאות הדיגיטלית-סך של 600א’ שח תמורת מניות המהוות 6% ב-G4P Merchavia’s CDx reports positive trial results for early detection of prostate cancer הוצאה לפועל אישרה את מכירת הנכס בנחלה בבת שלמה בכ- 4.1מ’ שח, המשך מ-26.10.17 מכתב מנכ”ל לבעלי המניות-סיכום 6 החודשים הראשונים של 2018 Cardiacsense completed 500K$ investment round on a 20M$ company valuation Positive Results in a Multi-Center Clinical Trial of CDx Juventas’s trial’s end-points for closing wounds on a diabetic foot not met CEO’s letter to shareholders – annual summary Memorandum of Understanding for investing $500,000 in Valens in exchange for allocation of about 6.25% of preferred shares Libental fully repaid loan worth NIS 7 million to Merchavia CDX signs exclusive commercialization agreement with Genomic granting a license to develop and commercialize tests for early diagnosis of prostate cancer CardiacSense completed raising funds from an external investor, after completion the company holds 7.86% Vacation of the property in Beit Shlomo completed, receiver appointed by the company will work for its sale Participation in the investment round of CardiacSense Ltd. Helsinki Committee approves start of trial for CardiacSense’s product Engaging in an investment agreement in CardiacSense Publishing an article in European Urology magazine about the final findings in CDX’s clinical trial Engaging in a non-binding Memorandum of Understanding to invest in CardiacSense The company is examining investing between NIS 1 million and NIS 4 million in each of 1-3 companies in the field of biomed and life sciences Merchavia Holdings has completed the sale of the balance of shares of Libental, owned by Baruch Ofir Merchavia Holdings will complete the sale of shares in Libental to Baruch Ofir for NIS 1.8 million – continued The company will invest $500,000 in Juventas as part of an investment round for 0.65% of preferred shares The company will sell its holdings in Libental for about NIS 3.3 million The deal has been completed for the sale of the full rights in T.G.R. to Dashan Intermediary results in the trial of CDX’s product for early diagnosis of prostate cancer The investment deal by a third party in CDX has been completed The third party will invest about $1.25 million in CDX The agreement is contingent on the sale of full rights in T.G.R. to Dashan for about NIS 7 million All articles loaded No more articles to load
זימון אסיפה ל-14.3.19-עדכון מדיניות תגמול לדירק’ ונ.משרה,תנאי כהונת מנכל ויור כולל הקצאת אופ+RSU ועוד,כתב הצבעה ועוד
Memorandum of Understanding for investing $500,000 in Valens in exchange for allocation of about 6.25% of preferred shares
CDX signs exclusive commercialization agreement with Genomic granting a license to develop and commercialize tests for early diagnosis of prostate cancer
CardiacSense completed raising funds from an external investor, after completion the company holds 7.86%
Vacation of the property in Beit Shlomo completed, receiver appointed by the company will work for its sale
The company is examining investing between NIS 1 million and NIS 4 million in each of 1-3 companies in the field of biomed and life sciences
Merchavia Holdings will complete the sale of shares in Libental to Baruch Ofir for NIS 1.8 million – continued
The company will invest $500,000 in Juventas as part of an investment round for 0.65% of preferred shares
